Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w
Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla
Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina t
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track
India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of
